# Ruxolitinib Plus Etanercept vs Ruxolitinib for Steroid-Refractory Severe Acute GVHD

> **NCT07184853** · NA · RECRUITING · sponsor: **First Affiliated Hospital of Zhejiang University** · enrollment: 122 (estimated)

## Conditions studied

- Graft vs Host Disease

## Interventions

- **DRUG:** Ruxolitinib (JAKAVI®)
- **DRUG:** Etanercept (Enbrel)

## Key facts

- **NCT ID:** NCT07184853
- **Lead sponsor:** First Affiliated Hospital of Zhejiang University
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-09-25
- **Primary completion:** 2027-09-25
- **Final completion:** 2028-09-25
- **Target enrollment:** 122 (ESTIMATED)
- **Last updated:** 2025-09-22

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07184853

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07184853, "Ruxolitinib Plus Etanercept vs Ruxolitinib for Steroid-Refractory Severe Acute GVHD". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07184853. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*